Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03026946
Other study ID # 54659
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 29, 2017
Est. completion date July 2022

Study information

Verified date February 2019
Source University Medical Center Groningen
Contact MLA Schuttelaar, MD, PhD
Phone +31503612520
Email m.l.a.schuttelaar@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of alitretinoin and cyclosporine in the treatment of patients with severe recurrent vesicular hand eczema.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date July 2022
Est. primary completion date July 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

Age = 18 years and = 75 years

- Severe or very severe recurrent vesicular hand eczema for a minimum duration of 3 months as defined by a Physician Global Assessment (PGA) using a validated Photoguide

- Refractory to standard therapy, defined as:

Patients received treatment with topical corticosteroids of class II or higher for at least 8 weeks within 3 months before enrolment, with either no response or a transient response. Patients had also received standard skin care, including emollients and barrier protection as appropriate, without significant improvement. Patients had avoided irritants and contact allergens, if identified, without significant improvement.

- Women of childbearing potential are required to use at least two forms of contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after finishing treatment; these women are required to take monthly pregnancy tests

- Able to provide written Informed Consent

- Able to speak and read the Dutch language

Exclusion Criteria:

General criteria prior to randomization

- Treated with alitretinoin or cyclosporine in the previous 3 months

- Other morphologic types of hand eczema as defined by the Danish Contact Dermatitis Group

- Patients with predominantly atopic dermatitis, in which the hands are also involved. (Patients with controlled atopic dermatitis, in which the hands are mainly affected, are eligible for inclusion.)

- Psoriasis of the hands

- Active bacterial, fungal, or viral infection of the hands

- Pregnant/lactating or planning to become pregnant during the study period

- Treatment with systemic medication or UV radiation within the previous 4 weeks

- Mentally incompetent

- Immunocompromised status

- Uncontrolled arterial hypertension (minimally 3 measurements). Systolic pressure > 160 mmHg or diastolic pressure > 95 mmHg, despite starting anti-hypertensive medication (first choice amlodipine 5 mg/day)

- Known or suspected allergy to ingredients in the study medications

- Inclusion in a study of an investigational drug within 60 days prior to start of treatment

- Current malignancy (other than successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix)

- Current active pancreatitis

- Evidence of alcohol abuse or drug addiction

- Malabsorption

- Currently active gout

- Recurring convulsions / epilepsy

- Living vaccine (including bacillus Calmette-Guérin (BCG), varicella, measles, mumps, rubella, yellow fever, oral polio and oral typhoid) in the last 2 weeks or the planned application of such a vaccine during the study period

- Chronic or recurrent infectious diseases

- Contact sensitizations with clinical relevance to the hands, in which exposure to allergens is not avoided.

- Hypervitaminosis A due to the use of vitamin A supplements containing >2000 IU

- Use of drugs with potential to change the effective dosis of study drugs within the previous 2 weeks Laboratory exclusion criteria post randomization

- Alanine aminotransferase (ALAT) and /or aspartate aminotransferase (ASAT) values > 200% of the upper limit of normal

- Impaired renal function as indicated by a clinically relevant abnormal creatinine value (to be determined by investigator or treating physician)

- Anemia as indicated by a clinically relevant lowered hemoglobin value (to be determined by investigator or treating physician) Alitretinoin specific

- Triglycerides > 200% of the upper limit of normal,

- Cholesterol or low density lipoprotein (LDL) cholesterol values > 200% of the upper limit of normal

- Uncontrolled hypothyroidism (to be determined by investigator or treating physician)

Cyclosporine specific:

- Impaired renal function as indicated by a clinically relevant abnormal creatinine value (to be determined by investigator or treating physician)

- Uremia

- Hyperkalemia

- Hyperuricemia in patients with a medical history of gout

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Alitretinoin
Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
cyclosporin A
Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (2)

Lead Sponsor Collaborator
University Medical Center Groningen ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response to treatment/hand eczema severity (Photoguide) 24 weeks (end of treatment)
Secondary Response to treatment/hand eczema severity (Photoguide) 12 weeks
Secondary Response to treatment/hand eczema severity (Hand Eczema Severity Index, HECSI) Week 4, 8, 12, 24
Secondary Time to response Week 4, 8, 12, 24
Secondary Patient reported improvement (Patient Global Assessment, PaGA) Week 12 and 24
Secondary Safety and tolerability (adverse events) Up to 24 weeks
Secondary Cost-utility. QALY's: registered direct/indirect costs, combined with EQ-5D outcome Week 12 and 24
Secondary Cost-effectiveness: registered direct/indirect costs combined with the primary and secondary effectiveness outcomes (Photoguide/HECSI) Week 12 and 24
Secondary Quality of Life: questionnaire. Week 12 and 24
See also
  Status Clinical Trial Phase
Completed NCT00576550 - A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema Phase 4
Completed NCT00404196 - LEO19123 Cream in the Treatment of Hand Eczema Phase 2
Completed NCT05763914 - A 24-week Single-blind Trial of Prevention of Hand Eczema in Cleaners N/A
Recruiting NCT03026907 - Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema Phase 3
Completed NCT00488241 - Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema Phase 4
Active, not recruiting NCT05906628 - Topical Ruxolitinib Evaluation in Chronic Hand Eczema Phase 2
Terminated NCT01826630 - A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema N/A
Recruiting NCT04449575 - Hand Eczema in the Health Care Sector
Withdrawn NCT05219864 - Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 Phase 3
Completed NCT01591785 - Treatment of Staphylococcus Aureus Colonization in Hand Eczema N/A
Completed NCT00826592 - Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis N/A
Completed NCT02664805 - Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema Phase 2
Completed NCT05471934 - Satisfaction Survey - Cicaplast Mains
Active, not recruiting NCT04512339 - Dupilumab in Severe Chronic Hand Eczema Phase 2
Completed NCT04375410 - Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic